Listeriolysin O (LLO) has been proposed as a potential carrier or adjuvant molecule in the vaccination field. However, the cytotoxic and pro-apoptotic effects of LLO are the major limitations for this purpose. Here, we have performed a preclinical safety evaluation and characterized a new potential adjuvant application for a non-cytolytic LLO mutant (dtLLO) to enhance and modulate the immune response against the envelope (E) protein from dengue virus. In addition, we have studied the adjuvant effects of dtLLO on human immune cells and the role of membrane cholesterol for the binding and proinflammatory property of the toxoid. Our in-vivo results in the murine model confirmed that dtLLO is a safer molecule than wild-type LLO (wtLLO), with a significantly increased survival rate for mice challenged with dtLLO compared with mice challenged with wtLLO (P < 0Á001). Histopathological analysis showed non-toxic effects in key target organs such as brain, heart, liver, spleen, kidney and lung after challenge with dtLLO. In vitro, dtLLO retained the capacity of binding to plasma membrane cholesterol on the surface of murine and human immune cells. Immunization of 6-8-week-old female BALB/c mice with a combination of dtLLO mixed with E protein elicited a robust specific humoral response with isotype diversification of immunoglobulin (Ig)G antibodies (IgG1 and IgG2a). Finally, we demonstrated that cholesterol and lipid raft integrity are required to induce a proinflammatory response by human cells. Taken together, these findings support a potential use of the dtLLO mutant as a safe and effective adjuvant molecule in vaccination.
Summary
Listeriolysin O (LLO) has been proposed as a potential carrier or adjuvant molecule in the vaccination field. However, the cytotoxic and pro-apoptotic effects of LLO are the major limitations for this purpose. Here, we have performed a preclinical safety evaluation and characterized a new potential adjuvant application for a non-cytolytic LLO mutant (dtLLO) to enhance and modulate the immune response against the envelope (E) protein from dengue virus. In addition, we have studied the adjuvant effects of dtLLO on human immune cells and the role of membrane cholesterol for the binding and proinflammatory property of the toxoid. Our in-vivo results in the murine model confirmed that dtLLO is a safer molecule than wild-type LLO (wtLLO), with a significantly increased survival rate for mice challenged with dtLLO compared with mice challenged with wtLLO (P < 0Á001). Histopathological analysis showed non-toxic effects in key target organs such as brain, heart, liver, spleen, kidney and lung after challenge with dtLLO. In vitro, dtLLO retained the capacity of binding to plasma membrane cholesterol on the surface of murine and human immune cells. Immunization of 6-8-week-old female BALB/c mice with a combination of dtLLO mixed with E protein elicited a robust specific humoral response with isotype diversification of immunoglobulin (Ig)G antibodies (IgG1 and IgG2a). Finally, we demonstrated that cholesterol and lipid raft integrity are required to induce a proinflammatory response by human cells. Taken together, these findings support a potential use of the dtLLO mutant as a safe and effective adjuvant molecule in vaccination.
Introduction
Adjuvant molecules are components in human vaccine formulations, which are added to increase the immunogenicity of antigens and to modulate the immune response against them [1] . Currently there is a limited number of licensed adjuvants for human use; consequently, basic studies and characterization of new molecules are of high priority in the vaccination field [2] . In recent years, listeriolysin O (LLO), the major virulence factor from Listeria monocytogenes, has been proposed as a potential microbial adjuvant/carrier molecule based on its biological properties, resulting in both the induction of the production of proinflammatory cytokines such as interleukin (IL)21b, IL-6, IL-8, tumour necrosis factor (TNF)-a [3] [4] [5] [6] [7] [8] and the capability of membrane pore-forming activity to introduce exogenous antigens into intracellular compartments [9, 10] . However, major limitations for the use of wild-type LLO (wtLLO) in human vaccination are the previously described pro-apoptotic effects and in-vitro cytotoxicity of wtLLO on different cell types [11] [12] [13] [14] [15] . In vivo, wtLLO is lethal to mice when they are injected intravenously (i.v.) or intraperitoneally (i.p.) with the toxin [16] [17] [18] . Also, injection of wtLLO into the footpads of mice led to terminal deoxynucleotidyl transferase dUTP nick end-labelling (TUNEL)-positive cells in the peripheral cortex and paracortex of the draining popliteal lymph node, confirming the pro-apoptotic activity of LLO in vivo [19] . Interestingly, deletions or mutations into domain 4 of the wtLLO structure abrogate the in-vitro cytotoxic and pro-apoptotic activities [20] [21] [22] , opening the possibility to use safer LLO variants than the wild-type molecule. Here, we show new evidence about the safety and adjuvanticity of a previously described detoxified non-haemolytic LLO mutant, named dtLLO [23] . This toxoid has been generated by introducing mutations in three key amino acids into the undecapeptide sequence in domain 4 of the LLO structure at residues 484, 491 and 492 [23] . These mutations were chosen because the selected amino acids have been postulated to be important for eventual membrane pore formation [21] . dtLLO has been tested previously as an effective adjuvant in tumour immunotherapy in a mouse model, and was found to potentiate anti-tumour-specific T cell responses. This molecule has pathogen-associated molecular pattern (PAMP) properties, and activates the innate immune response in a Toll-like receptor (TLR)-4 independent mechanism [23] .
There is limited evidence for the in-vitro cytotoxic effects of dtLLO. A previous study has demonstrated the reduced lytic effect of dtLLO on sheep red blood cells (RBCs) . No other studies have addressed the issue of toxic activity on other cell populations.
Interestingly, there are no published studies that address specifically the in-vivo toxicity of dtLLO. In this paper we describe a preclinical safety evaluation using a single-dose i.v. administration of dtLLO in the mouse model to identify potential target organs for toxicity. In addition, we have evaluated a new adjuvant application for this noncytotoxic LLO mutant to potentiate and modulate the humoral immune response against microbial antigens from dengue virus (DENV), a pathogen of global public health concern. Finally, we evaluated the capacity of dtLLO to induce a proinflammatory response by human immune cells such as monocyte-derived dendritic cells (moDCs) and peripheral blood mononuclear cells (PBMCs), and found that the adjuvant effect of dtLLO on human cells is dependent upon the retention of dtLLO to bind to cholesterol.
Materials and methods

Purification of wtLLO and dtLLO
Construction of plasmids with the cloned sequences for wtLLO and dtLLO has been described previously [23] . BL21 (DE3) chemically competent cells (Invitrogen, Carlsbad, CA, USA) were transformed with the recombinant protein expression plasmids and grown in Luria-Bertani (LB) medium containing 30 lg/ml of kanamycin (Sigma Aldrich, St Louis MO, USA). wtLLO and dtLLO were purified as described previously [24] . Protein expression was induced in BL21 cells by the addition of 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) and the culture was incubated, shaking at 308C for 6 h. The purification was realized by a polyhistidine motif contained in the cterminal region of the proteins to allow for isolation on a nickel-nitrilotriacetic acid (Ni-NTA) column (Qiagen, Venlo, Limburg, the Netherlands), following the manufacturer's instructions. The purified recombinant proteins were dialyzed extensively against storage buffer [50 mM phosphate/acetate (pH 6.0), 1 M NaCl, 1 mM ethylenediamine tetraacetic acid (EDTA) and 5 mM dithiothreitol (DTT)]. The recombinant proteins were purified further by passage over Detoxy-Gel endotoxin removal columns (ThermoFisher Scientific, Waltham, MA, USA). The purity and integrity of the recombinant proteins were confirmed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Endotoxin levels were measured by chromogenic Limulus amoebocyte lysate test (Lonza, Basel, Switzerland), according to the manufacturer's protocol. Endotoxin levels were < 1 EU/mg of protein.
control; wtLLO and dtLLO final concentrations covered a range from 25 to 0Á02 lg/ml. After incubation, RBCs were spun out at 600 g to remove unlysed RBCs. The supernatants were collected and the degree of haemolysis was evaluated by measuring the absorbance of haemoglobin (405 nm) released from erythrocytes.
Ethics statement
The animal study was conducted in compliance with the Good Laboratory Practices and Use of Laboratory Animals (NOM-062-ZOO-1999). The study was approved by the Ethics Committee of the Instituto de Investigaciones M edico-Biol ogicas, Universidad Veracruzana. For survival experiments, mice were monitored closely for signs of illness for 10 min and were euthanized humanely when the time was reached.
Systemic toxicity of wtLLO and dtLLO in mice
Female 6-8-week-old BALB/c mice were challenged i.v. with 20 lg of recombinant dtLLO or wtLLO diluted in a 100 ll volume of sterile physiological saline solution (PSS). A negative control group was included in the experiment, challenging with 100 ll volume of PSS. All animals were monitored during the first 10 min-1 h after the challenge to record mortality. Evaluation of the acute systemic toxic effects on key target organs was performed. The organ weight and histopathology were examined. Heart, liver, spleen, lungs, kidneys and brain were collected from all mice groups after they died or after the first 10 min or 1 h post-challenge, depending on the mortality and survival of each group. Organs were fixed with 4% buffered formalin, processed and embedded in paraffin. Tissue sections were stained with haematoxylin and eosin (H&E).
TUNEL assay
Apoptosis in vivo was assessed by TUNEL assay. Lungs, liver, heart, spleen and kidneys were fixed overnight at 48C in 10% buffered formalin and embedded in paraffin. An in-situ Cell Death Detection Kit (Roche Applied Science, Indianapolis, IN, USA) was used to carry out TUNEL staining on sections of 5-lm thickness and fluorescence detection, according to the manufacturer's instructions. A positive control was included in the experiments for tissue sections from each organ analysed. The tissue sections were permeabilized and treated with DNAse 1 recombinant 1500 U/ml in 50 mM Tris HCl, pH 7Á5, 10 mM MgCl2, 1 mg/mL BSA buffer for 10 min at 115 to 125 C to induce DNA strand breaks. Finally, the slides were rinsed again with PBS and analysed using a fluorescence microscope and excitation wavelength in the range of 450-500 nm and detection in the range of 515-565 nm (green).
Binding capacity of wtLLO and dtLLO to murine cholesterol cell membranes Spleens were removed aseptically from BALB/c mice and squeezed between a cell strainer and a syringe plunger to prepare a single-cell suspension. Cells were pooled and treated with 0Á83% ammonium chloride in 170 mM TrisHCl (pH 7Á65) to lyse erythrocytes. Cells were washed twice with RPMI-1640 medium and suspended at 2 3 10 6 cells/ ml density in RPMI-1640 medium. Spleen cells (13 10 6 ) were stimulated with dtLLO 10 mg/ml or wtLLO 10 mg/ml in RPMI-1640 medium for 10 or 20 min at low temperature (48C) to prevent membrane recycling and internalization of the antigens. After the incubation time was over, the cells were fixed with paraformaldehyde (PFA) 4% for 20 min. Then, spleen cells were blocked with bovine fetal serum 5% and stained with an anti-LLO primary rabbit antibody (Abcam, Cambridge, UK), followed by an Alexa Fluor 488 anti-rabbit IgG (Invitrogen). The stained cells were analysed in an Accuri C6 flow cytometer. To evaluate the interaction with plasma membrane cholesterol, spleen cells were treated previously with methyl-beta cyclodextrin (mbCD) (Sigma Aldrich) 5 mM for 30 min before the stimulation with wtLLO and dtLLO;the cells were washed twice with medium and then stimulated with the proteins, and were finally fixed and stained as described previously.
In-vivo proinflammatory effect of dtLLO Evaluation of E-protein-specific antibody titres Serum-specific total IgG or IgG1 and IgG2a isotypes titres for E protein from DENV4 were measured by ELISA. Briefly, ELISA plates were coated with recombinant E protein at 5 lg/ml diluted in carbonate buffer, pH 9Á6, incubated overnight at 4 C. Plates were washed five times with PBS containing 0Á05% Tween 20 (PBST) and blocked for 1 h with PBS containing 0Á5% BSA (Sigma Aldrich). Serially diluted serum samples were incubated for 2 h at 37 C. Plates were washed again, as described previously. Specific E protein antibodies were revealed adding horseradish peroxidase (HRP)-labelled goat anti-mouse IgG, IgG1 or IgG2a at a dilution of 1 : 2500 (Jackson ImmunoResearch, West Grove, PA, USA) antibodies. Plates were washed as described previously, followed by the addition of 2, 2'-azinobis (3-ethylbenzothiazoline-6-sulphonic acid)-diammonium salt (ABTS) substrate (Sigma Aldrich). Finally, optical density (OD) was measured in an ELISA plate reader (Awareness Technology Inc., Palm City, FL, USA). Titres were calculated through linear regression equations as the reciprocals of the serum dilutions that produced OD405 nm values of 0Á2 above the blank, and the titres were reported in ELISA units per ml (EU ml 2 1 ).
Binding capacity of dtLLO to human cholesterol membranes
PBMCs were isolated from healthy blood donors using density gradient centrifugation on Lymphoprep (Axis Shield, Dundee, Scotland, UK), according to the manufacturer's instructions. PBMCs (1 3 10 6 ) were stimulated with dtLLO 1 mg/ml or wtLLO 1 mg/ml in RPMI-1640 medium for 10 or 20 min at low temperature (on ice) to prevent membrane recycling and internalization of the antigens. After incubation, the cells were fixed with PFA 4% for 20 min. Then, PBMCs were blocked with 2% BSA-PBS and stained with an anti-LLO primary antibody (Abcam), followed by an Alexa Fluor 488 anti-rabbit IgG (Invitrogen). The stained cells were analysed in an Accuri C6 flow cytometer. To evaluate the interaction with cholesterol of PBMC membranes, cells were treated previously with mbCD (Sigma Aldrich) at 5 mM for 30 min before stimulation with wtLLO and dtLLO, then the cells were washed, stimulated and finally fixed and stained as described previously.
Stimulation assays with human immune cells
For human dendritic cell (DC) differentiation, PBMCs were incubated for 2 h in 75 cm 2 plastic culture flasks (Corning, New York, NY, USA). The non-adherent fraction was washed out thoroughly, and isolated adherent monocytes were incubated in RPMI-1640 medium in the presence of human granulocyte-macrophage colonystimulating factor (GM-CSF) (1Á5 ng/ml; Peprotech) and human IL-4 (15 ng/ml; Peprotech) for 6 days. Human DCs were analysed for CD1a, CD11c, CD14 and major histocompatibility complex (MHC) II expression by flow cytometry to confirm differentiation and DC phenotype. PBMC (1 3 10 6 or 2 3 10 5 ) human DCs were stimulated with dtLLO 1 mg/ml or LPS 1 mg/ml (Sigma Aldrich) in the presence or absence of 50 mg/ml of polymyxin B (Invivogen, San Diego, CA, USA). After 24 h stimulation, the supernatants were collected and tested for cytokine production by ELISA. To evaluate if the interaction of dtLLO with cholesterol is required for proinflammatory property on human immune cells, PBMCs (1 3 10 6 ) were incubated with mbCD (Sigma Aldrich) at 1 and 5 mM for 30 min at 378C, washed with medium and then stimulated with dtLLO (1 mg/ml) for 4 h at 378C. The supernatants were collected and tested for cytokine production by ELISA.
In other experiments, stimulation of PBMCs with dtLLO (1 mg/ml) was performed in the presence of fisetin (Sigma Aldrich) at 7 and 28 lM doses. For the experiments with mbCD and fisetin, the cell viability was tested before and after the stimulation times using trypan blue, with no cytotoxic effects observed.
Analysis of cytokines
Concentrations of murine IL-6 and IL-12 and human TNF-a, IL-6, IL-12, IL-10 in murine serum samples, or culture supernatants from stimulated human immune cells were measured by commercial ELISA (Peprotech). Briefly, ELISA plates (Corning) were coated overnight with specific capture antibodies. Next day, the plates were blocked with 0Á5% BSA (Sigma Aldrich) and washed with PBS-Tween (PBST). Murine serum samples from in-vivo experiments or cell culture supernatant from in-vitro-stimulated human cells were then added and incubated at room temperature for 2 h. A linear standard curve was generated using appropriate recombinant cytokines. After washing with PBST, specific biotin-conjugated anti-cytokine antibodies were added and allowed to incubate for 2 h at room temperature. Plates were washed with PBST and an avidin-HRP conjugate was added for 30 min. Finally, the plates were washed again with PBST, followed by incubation with the substrate ABTS (Sigma Aldrich). Absorbance was measured at 450 nm using an ELISA plate reader. The concentrations for each cytokine in the sample were determined by extrapolating OD values using the standard curve. The values were expressed in pg/ml.
Statistical analysis
The statistical significance of the differences between IgG, IgG1 and IgG2a titres and cytokine concentrations were analysed using the one-way analysis of variance (ANOVA) statistical test with Tukey's post-test, using GraphPad Prism software version 6.01 (GraphPad Software, San Diego, CA, USA). P-values < 0Á05 were considered statistically significant. Significant P-values for all comparisons are depicted in the figures as follows: *P < 0Á05; **P < 0Á01; and ***P < 0Á001; non-significant P-values are shown as n.s.
Results
Safety evaluation for dtLLO
The biological ability of adjuvant molecules to enhance or modulate the immune response to different antigens is well documented. However, the use of adjuvants represents a potential safety risk for the host, which needs to be evaluated in preclinical studies. Thus, the first aim of our study was to evaluate the safety of dtLLO in vitro and in vivo, first as an individual molecule and then as part of an experimental vaccine formulation. Given that the cytolytic activity could be a major problem for LLO in biomedical applications, we evaluate the lytic potential of both dtLLO and wtLLO in a haemolysis assay, using human erythrocytes as substrate. Our results confirm the data reported previously for bovine and sheep RBCs, where wtLLO exhibited a highly haemolytic activity on human erythrocytes in a wide range of concentrations (25-0Á01 lg/ml) (Fig. 1a) . In contrast, dtLLO did not show detectable haemolytic activity, even at the highest concentrations (25-12Á5 lg/ml) (Fig. 1a) . In order to evaluate the safety of the dtLLO mutant, we performed further experiments to determine dtLLO safety in an in-vivo mouse model. We know from previous studies that i.v. administration of wtLLO causes a convulsive, rapidly fatal reaction in mice [16] [17] [18] , and that 200 lg of dtLLO can be administered safely to C57BL/6 mice subcutaneously (s.c.) [23] . In addition, i.v. injection of wtLLO causes high lethality within 4 or 5 min. Electrocardiograms from LLO-treated mice indicate serious alterations in heart rate and rhythm, suggesting damage to contractile and pacemaker cardiac tissue [18] . On the basis of this evidence, we compared the systemic effects and lethality rate between dtLLO and wtLLO. We challenged groups of female BALB/c mice with a high and lethal dose of wtLLO (20 lg per mouse, i.v.) and compared with the group of mice challenged with the same dose of dtLLO or the group of mice injected only with PSS as a negative control. For ethical reasons, and given the previous information about the effects and time in which wtLLO causes high lethality rates [16, 18] , we decided to perform these experiments with the minimum number of animals per group required to achieve statistical significance (five mice per group). All experimental mice groups were monitored for 10 min to compare the lethality rate. As expected, i.v. challenge with wtLLO resulted in a high percentage of lethality (80%) of BALB/c mice in an interval of 2-10 min (Fig. 1b) . Respiratory failure and convulsions preceded death. In contrast, the group of mice challenged with dtLLO showed 100% survival (Fig. 1b) . In an independent experiment, mice immunized (n 5 15) i.p. with 20 lg of dtLLO were monitored for 4 weeks after dtLLO administration, with 0% lethality (data no shown). The above results confirm that the molecule dtLLO was a detoxified and safe protein, even when the toxoid was administered to the mice by systemic routes.
While there is a clear description of the toxic effects of wtLLO on different tissues during an in-vivo bacterial infection [26] , little is known about histopathological findings in mice challenged with purified wtLLO, and nothing is known about the toxicity of recombinant dtLLO on key target organs. To address this issue, the severity of the tissue damage in mice was assessed through conventional histological analysis. Spleen, liver, lungs, kidney, heart and brain from mice challenged with dtLLO, wtLLO or PSS were collected during or at the first 10 min or 1 h of antigen injection (depending on the length of time the mice survived). Mice injected with wtLLO exhibited multiple focal haemorrhages, sarcoplasmic vacuoles and hypercontracted fibres in the heart. The lungs showed oedema and intra-alveolar haemorrhage and focal subpleural haemorrhage. The kidneys showed generalized congestion, focal haemorrhage and vacuolation of epithelial cells of distal tubules. Furthermore, livers and spleen showed multiple haemorrhages and dilatation of centrilobular veins. We observed subarachnoid haemorrhage in the brain, especially in the temporal lobes and brain stem. Focal haemorrhage, neuropil oedema and vacuolation of neurones were observed in sections of brain stem. Organs from mice treated with PSS or dtLLO exhibited normal tissue structure with minimal congestion. A summary of the histopathological findings in the experimental groups is shown in Table 1 . Representative pictures from the tissue damages of lungs, spleen, liver, kidney, heart and brain in the immunized mice groups with wtLLO and dtLLO are shown in Fig. 2 . Because recombinant or purified wtLLO is highly lytic for the cells and may also trigger apoptotic cell death by itself in vitro or during infection by LM in vivo in the spleen, lymph nodes, liver and brain [19, 27, 28] , we examined if dtLLO mutant protein retains the pro-apoptotic effects of wtLLO. To answer this issue, we analysed the presence of apoptotic cells in the same mice tissue sections that we collected for the H&E staining after 60 min post-challenge with dtLLO. Apoptotic cells were detected by TUNEL assay as described in the Material and methods section. No evidence of significant apoptotic cells was found in all the organs analysed, including lung, spleen, heart, kidney and liver (Fig. 3) . Taken together, the mice lethality rate, immunohistochemistry analysis of the mice tissue sections and TUNEL assay results after challenge with dtLLO confirmed that this toxoid is a safe molecule without significant systemic toxic effects, such as those observed with wtLLO.
Cholesterol-dependent binding of dtLLO to murine cell membranes
Some of the most important biological functions of LLO depend upon the interaction with cell membranes through cholesterol, which is a key receptor. It is well known that a conserved undecapeptide sequence in domain 4 of LLO structure is considered crucial for membrane binding and cytotoxic activity [29] . However, a previous report has shown that mutations in two tryptophan at positions 491 and 492 in this undecapeptide sequence do not prevent LLO from binding to cells [30] . To address if dtLLO can bind to cell membranes, we performed experiments using pulsed murine splenocytes with wtLLO or dtLLO for 10 and 20 min on ice to prevent membrane recycling and the internalization of the antigens. The cells were then fixed with PFA, and evaluated by flow cytometry as described previously in the Material and methods section. As shown in Fig. 4a-d , dtLLO conserves the ability to bind with high affinity to the cell membranes of murine splenocytes, similarly to wtLLO. Interestingly, the binding property of dtLLO to the cells depend upon the presence of cholesterol in cell membranes, because pretreatment of splenocytes with mbCD, a pharmacological agent used commonly to remove membrane cholesterol, abrogates the binding of dtLLO to the splenocyte membrane significantly (Fig. 4e-h ). 
In-vivo induction of proinflammatory cytokines by dtLLO
A major mechanism by which adjuvant molecules potentiate and modulate the immune response against vaccine antigens is by inducing the production of a variety of proinflammatory cytokines, which help to shape the adaptive immune response. In order to test if dtLLO retains the ability to induce a proinflammatory response we performed some invivo experiments, immunizing female BALB/c mice (n 5 11 each group) i.p. with the toxoid (20 lg per mouse) and comparing with a positive control (LPS). We decided to test two representative proinflammatory cytokines, IL-6 and One and 2 h after the challenge with dtLLO, both IL-6 and IL-12 reached high serum levels. However, the inflammatory response induced by the dtLLO is considerably lower compared to the robust production of IL-6 and IL-12 induced by LPS. Collectively, these results suggest that dtLLO delivered i.p. acts as a safe adjuvant molecule inducing in-vivo activation and increasing the production of key innate cytokines such as IL-6 and IL-12.
Evaluation of the efficacy of dtLLO as an adjuvant molecule to potentiate humoral immune response to dengue antigens
Given our previous results, confirming that dtLLO retains its binding and proinflammatory properties in the absence of adverse effects and without in-vivo toxicity, we next evaluated the adjuvant potential of dtLLO for the E protein from DENV, a re-emerging pathogen and a major public health concern worldwide. Recently a licensed vaccine for dengue virus has become available to protect against this viral pathogen; however, the performance and protection generated by this vaccine is controversial [31] The E protein is a key surface viral glycoprotein involved in the binding of DENV to the cell receptors. E protein is the immunodominant antigen, and elicits protective immunity through the induction of specific antibodies [32] . Using the experimental vaccination approach, consisting of a single combination of dtLLO (20 lg/ml) mixed with E protein (5 lg/ml) from DENV4, we assessed the adjuvant capacity of dtLLO to increase and modulate the humoral immune response against this viral antigen. A group of mice immunized with alum adjuvant combined with E protein (5 lg/ml) was included in the experiments to compare the humoral immune response induced by these two different adjuvants. A control mouse group immunized with E protein alone (5 lg/ml) was also included. After a single immunization, total IgG titres (Fig. 6a ) and IgG1 and IgG2a (Fig. 6b,c) isotypes were measured in all experimental groups on day 14 post-immunization (primary response). All animals received a boost dose on day 14 and the total IgG titres (Fig. 6d) and the IgG1 and IgG2a (Fig. 6e ,f) isotypes were measured again on day 28 after the boost dose. For both primary and secondary responses, the dtLLO-E protein combination elicited higher titres of total specific IgG compared to E protein alone (P < 0Á05 and P < 0Á01, respectively), without significant differences with respect to the total IgG titres induced by the alum-E protein formulation in the primary response (P > 0Á05) but with a statistically significant difference in the secondary response (P < 0Á001). Furthermore, while E protein alone or mixed with alum induced a typical Th2 immunoglobulin pattern characterized by the production of E-protein specific IgG1 titres, the formulation of E protein plus dtLLO adjuvant elicited a balanced production of T helper type 1 (Th1) (IgG2a) and Th2 (IgG1) isotypes, with higher titres of both isotypes than the E protein alone. For the IgG2a isotype, dtLLO induced a more potent response than the alum-E protein formulation in both primary (P < 0Á001) and secondary responses (P < 0Á01). No adverse effects of the experimental vaccine could be seen after the first and second immunizations using dtLLO as an adjuvant i.p.
Induction of proinflammatory cytokines in PBMCs and monocyte-derived dendritic human cells by dtLLO
In order to explore the potential use of dtLLO as an adjuvant in human vaccination we evaluated the proinflammatory capacity of dtLLO on human immune cells, such as PBMCs and DCs. PBMCs (1 3 10 6 ) or DCs (2 3 10 5) were stimulated in vitro with the toxoid (1 lg/ml), LPS (1 lg/ml) or medium alone for 24 h. Although endotoxin contaminant concentrations in the recombinant dtLLO batch were very low, polymyxin B (PMB), an antibiotic known to inhibit the biological activities induced by LPS, was added as an experimental control. The supernatants were harvested for assessment of cytokine secretion. The concentrations of IL-6, TNF-a, IL-12 and IL-10 were determined (Fig. 7) . Strong IL-6, TNF-a and IL-10 production was observed in dtLLO-stimulated PBMCs (IL-6 mean 5 6019Á25 ng/ml, TNF-a mean 5 2230Á61 ng/ml, IL-10 mean 5 889Á64 ng/ml), with a moderate production of IL-12 (mean 5 489Á08 ng/ml) compared with the levels measured in LPS-stimulated PBMCs. Interestingly, the stimulation of human DCs with dtLLO also induced high levels of TNF-a (mean 5 3536Á71 ng/ml) and IL-10 (mean 5 930Á66 ng/ml), with moderate levels of IL-6 and IL-12, compared with the production of these cytokines in LPS-stimulated DCs. Taken together, the cytokine analysis in dtLLO-stimulated human immune cells confirmed that the adjuvant property for this toxoid is conserved on human cells.
Cholesterol-dependent binding of dtLLO to human PBMCs membranes
To confirm the dtLLO capacity to bind to human PBMCs membranes, PBMCs (1 3 10 6 ) were pulsed with wtLLO (1 lg/ml) or dtLLO (1 lg/ml) on ice to prevent membrane recycling and internalization of the antigens. They were fixed later with PFA, and protein binding to the cell membrane was confirmed by flow cytometry. As shown in Fig. 8a-d , dtLLO retains the ability to bind with high affinity to human cell membranes, similar to that of wtLLO. As described previously for murine cells, pretreatment of PBMCs with methyl-b-cyclodextrin (mbCD) (5 mM) abrogates significantly the binding of dtLLO to human cell membrane (Fig. 8e-h ), demonstrating the key role of cholesterol as a binding receptor for the toxoid.
Cholesterol depletion abrogates cytokine production in dtLLO-activated human PBMCs
A previous report on dtLLO biological activity has shown that the toxoid induces up-regulation of proinflammatory cytokine mRNAs and over-expression of co-stimulatory molecules in dtLLO-stimulated bone marrow-derived DCs (BMDCs) from both wild-type (C57BL6) and TLR-4 2/2 -deficient mice [23] , discarding a TLR-4-dependent mechanism for the immunomodulatory activity of dtLLO. Also, the adjuvant activity of dtLLO cannot be explained by cell activation by the pore-forming property. Because the toxoid preserves its binding capacity to cell membranes, we decided to evaluate the biological role of cholesterol for the proinflammatory activity of dtLLO on human PBMCs. We know that the integrity of cholesterol-enriched microdomains, called lipid rafts, of eukaryotic cells is required for both Groups of BALB/c mice (n 5 10) were immunized intraperitoneally with E protein (5 lg per mouse), E protein (5 lg per mouse) plus alum or E protein (5 lg per mouse) plus dtLLO (20 lg per mouse). All animals received a booster injection of the same dose and route on day 14. Sera were collected from mice 14 and 28 days after the first immunization. Pre-immune sera (day 0) were collected and used as basal levels for comparison. Comparison of primary (a) and secondary total immunoglobulin (Ig)G titres (d) using alum or dtLLO as adjuvants for E protein. Primary IgG1 (b) and IgG2a (c) antibodies titres or secondary IgG1 (E) and IgG2a (F) antibodies titres were evaluated by enzyme-linked immunosorbent assay (ELISA). One representative experiment of two independent experiments is shown. The results are expressed as the mean 6 standard deviation (s.d.). Statistical significance was determined by the analysis of variance (ANOVA) statistical test with Tukey's post-test. Significant P-values for all comparisons are shown as follows: *P < 0Á05; **P < 0Á01; ***P < 0Á001. Non-significant P-values are shown as n.s.
Safety and adjuvanticity of a detoxified LLO mutant V C 2016 British Society for Immunology, Clinical and Experimental Immunology, 188: 109-126 activation and cell signalling. Therefore, we explored whether cholesterol depletion and raft disruption in PBMCs could influence the proinflammatory cytokine production induced by dtLLO. Pretreatment of PBMCs (1 3 10 6 ) with mbCD and subsequent stimulation with dtLLO abrogated completely the IL-6 and TNF-a production in activated human PBMCs in an mbCD dose-dependent manner (Fig. 9a,b) . The concentrations of mbCD were titrated in initial experiments without adverse effects on viability for the tested times. In summary, our results suggest that the immunomodulatory effects of dtLLO on human cells are dependent upon binding to cholesterol and the integrity of lipid rafts. Human PBMCs were treated with 1 lg/ml of dtLLO, 1 lg/ ml of lipopolysaccharide (LPS) or maintained with RPMI-1640 medium as negative control in the presence or absence of polymyxin B (PMB) (a-d). Human DCs were also stimulated with dtLLO 1 lg/ml, LPS 1 lg/ml or RPMI-1640 medium as negative control in the presence and absence of PMB (e-h). The culture supernatants were collected for screening of cytokine production, interleukin (IL)26, tumour necrosis factor (TNF)-a, IL-12 and IL-10. Statistical significance was determined by the analysis of variance (ANOVA) statistical test with Tukey's post-test. Significant P-values for all comparisons are shown as follows: **P < 0Á01; ***P < 0Á001. Non-significant P-values are shown as n.s. One representative experiment of three independent experiments is shown.
Fisetin abrogates cytokine production in dtLLOactivated human PBMCs
In order to address the mechanism and signalling pathway involved in the activation of human cells mediated by dtLLO we used the flavonoid fisetin (3, 7, 3 0 , 4 0 -tetrahydroxyflavone), which has been described as a suppressor of the nuclear factor (NF)-jB signalling pathway [33] . Fisetin blocks the phosphorylation and degradation of IjBa, which leads in turn to suppression of the phosphorylation and nuclear translocation of the p65 NF-jB subunit [33] . Treatment of PBMCs with dtLLO in the presence of the highest concentration of fisetin tested abrogated the production of TNF-a, IL-6, IL-12 and IL-10 significantly ( Fig. 10a-d ). Cell viability was tested before and after stimulation using trypan blue, with no cytotoxic effects observed (data not shown). These results suggest that the NF-jB signalling pathway is involved in the inflammatory process induced by dtLLO. Then, cells were stimulated with dtLLO (1 lg/ml) for 4 h at 37 C and the supernatants were collected and analysed for production of (a) interleukin (IL)-6 and (b) tumour necrosis factor (TNF)-a. Significant P-values for all comparisons are shown as follows: *P < 0Á05; **P < 0Á01; ***P < 0Á001. Non-significant P-values are shown as n.s. One representative experiment of three independent experiments is shown.
Discussion
Adjuvants constitute an essential element to improve and modulate the immune response against antigens included in vaccine formulations. Characterization of the safety and efficiency of these molecules in the vaccination field is the first, and one of the most important points to consider, before their clinical use. Here, we investigated the in-vivo safety and adjuvant properties of dtLLO, a non-cytolytic LLO mutant. First, the in-vitro toxicity of the wtLLO and dtLLO was assessed using RBCs from human donors. As described previously for sheep RBCs [23] , dtLLO did not show detectable haemolytic activity, even at the highest concentration of protein that we tested. These results confirm that the mutations introduced into the undecapeptide sequence abrogates completely the haemolytic effects, regardless of the species of RBCs used. In order to evaluate a potential systemic toxicity, the lethality rate after intravenous administration of dtLLO or wtLLO was determined. The results observed after i.v. challenge with the toxoid confirmed the findings of Wallecha et al. [23] , that dtLLO is also a nontoxic molecule in vivo. The high survival rate of mice after i.v. challenge with dtLLO is in agreement with the survival rate observed after immunization using dtLLO as an adjuvant i.p., with a similar dose to that administered i.v.
To the best of our knowledge, our study has performed the first histopathological description of the toxic effects of recombinant wtLLO and dtLLO on target organs such as brain, lung, heart, spleen, liver and kidney. Mice challenged with wtLLO exhibited multiple focal haemorrhages in heart, lung, liver and brain. The hypercontracted fibres observed in the heart caused by wtLLO toxicity explained previous findings on functional damage to heart muscle in LLO-challenged mice [18] . Systemic wtLLO administration induced lung oedema, intra-alveolar haemorrhage and focal subpleural haemorrhage, suggesting that all these injury signals may lead to respiratory failure associated with cardiotoxic effects. In kidney, wtLLO induced epithelial vacuolization, which suggests a direct toxic effect of this toxin on the renal tubule. Moreover, neurotoxicity signals after challenge with wtLLO were evident after a few minutes of toxin administration. The main anatomical disorders in brain included severe congestion, focal subarachnoid haemorrhage, extravasation of proteinaceous material, ischaemic neurones in the cerebellum (Purkinje cells, dentate nucleus) and hippocampus neuropil oedema, vacuolation of neurones and focal haemorrhage (brain stem). Thus, the central nervous system is another primary target organ of wtLLO. The rapid neurotoxicity observed after a few minutes of wtLLO administration suggests a direct effect of the toxin on the central nervous system. In contrast with the detrimental systemic effects of wtLLO, histopathological analysis revealed no significant abnormalities in tissue of brain, lung, heart, kidney, liver and spleen in the mice group challenged with dtLLO. Based on previous in-vitro scientific evidence concerning the rapid pro-apoptotic effects of wtLLO on lymphocytes, which is characterized by activation of caspases as quickly as 30 min [19] , and the previous results on the toxic effects on the C3.F6 cell line after only 60 min incubation with wtLLO [30] , we examined the tissue sections of mice challenged with dtLLO for apoptotic cell death. Our in-vivo results are in agreement with previous in-vitro results with other LLO mutants, showing that mutation of the tryptophans to alanines at both residues 491 and 492 or at only residue 492 in the wtLLO amino acid sequence led to a significant reduction in the pro-apoptotic activity of LLO [30] . Taken together, the immunohistochemistry results and TUNEL assay confirmed that dtLLO toxoid is a safe molecule without significant systemic toxic effects, such as those observed with wtLLO.
Other important findings in our study included evaluation of the proinflammatory potential of dtLLO in vivo after i.p. challenge of mice with the toxoid. It is well known that not all inflammatory molecules can be considered as safe adjuvants. The extreme toxicity of some microbial molecules such as LPS is a major limitation for this purpose. Previously, dtLLO has been tested for its potential to induce the expression of inflammatory genes such as TNF-a or IL-6 using an in-vitro approach [23] ; however, no evidence was provided about the magnitude of the inflammatory response induced by the toxoid in vivo. In order to test the immunostimulatory properties of dtLLO, in our study we evaluated the production of two typical inflammatory mediators: IL-6, a nonspecific cytokine, and IL-12, a polarizing cytokine, compared against a very toxic and highly inflammatory molecule, LPS. Our results showed that dtLLO induced low and tolerable levels of inflammation compared to the high levels of inflammation induced by LPS. We know from previous studies that low levels of inflammatory cytokines are sufficient to orchestrate specific immune responses effectively [34] . Low levels of inflammatory cytokines induced by the toxoid can represent an advantage in the use of this molecule in vivo, such that it is not a toxic or highly inflammatory molecule with adverse effects for the host, but is effective in stimulating and modulating the innate immune system in vivo. In this context, our observations are extremely important in predicting the biological behaviour of dtLLO as a potential safe adjuvant in human vaccination compared with the traditional toxic and highly inflammatory effects of different adjuvants already licensed, such as alum or adjuvant candidates that are currently under clinical investigation, such as Toll-like receptor ligands [35] or oil-in-water emulsions [36] . Some of these adjuvants have the disadvantage of promoting antigen deposition, which can induce adverse effects such as granuloma formation, subcutaneous nodules and contact hypersensitivity triggered by T cells that infiltrate the injection site [37] .
In addition to the safety evaluation, we tested here a new application for dtLLO as an adjuvant molecule to enhance the humoral-specific immune response against DENV antigens. Our results showed that specific IgG antibodies against E protein from DENV4 were induced successfully at high levels for the experimental vaccine containing dtLLO as adjuvant. Interestingly, when dtLLO was used in combination with E protein we detected a diversified profile of IgG1 and IgG2a isotypes, in contrast to the predominance of IgG1 isotype induced by the formulation containing alum. While the IgG1 isotype is associated with a Th2 profile, production of IgG2a is associated with a Th1 immune response [38] . The in-vivo production of IL-12 in mice after immunization with dtLLO can explain the humoral profile for E protein from DENV that we found, particularly the induction of specific anti-E-protein IgG2a antibodies. Considering dtLLO as an effective immunomodulatory molecule with the advantage of promoting IgG isotype diversification is a remarkable result, and is consistent with a study using a B cell receptor idiotype (Id) conjugated with a non-haemolytic form of LLO, compared with the Id conjugated with keyhole limpet haemocyanin (KLH) as immunotherapy for non-Hodgkins lymphoma. The Id-LLO induced a more powerful Th1 response, characterized by high-titre IgG2a anti-Id antibodies and the presence of CD4 1 cells secreting IFN-g [39] . This evidence supports a potential advantage in the use of dtLLO with respect to the alum as an effective adjuvant to induce Th1 responses. Modulation towards Th1 responses is required to gain protection mainly against intracellular pathogens, a clear problem with the current use of alum as an adjuvant in human vaccination.
Antibody isotype diversification is essential for the immune system to mount protective humoral responses using different biological and effector functions. Previously, it has been described for other experimental dengue vaccines that neutralizing activity can be associated with either IgG1 or IgG2a antibodies [40] . In addition to the neutralizing property, IgG2a antibodies can mediate complement activation and ADCC mechanism, which together are essential biological functions for viral immunity.
It remains to be evaluated in future studies if dtLLO can enhance the cellular immune response against microbial antigens from DENV CD4 1 and CD8
1
-specific T cells, in the same way as shown previously against tumour antigens [23] .
In order to explore fully the potential use of dtLLO as an adjuvant in human vaccination, we analysed the proinflammatory properties of the toxoid on human immune cells. As reported previously using murine cells using an in-vitro approach [23] , or our own in-vivo findings in the mouse model, we found that dtLLO preserves the proinflammatory property on human immune cells. A robust production of inflammatory mediators such as IL-6 and TNF-a was induced after stimulation of human PBMCs with dtLLO after 24 h of stimulation. Interestingly, medium levels of IL-12, a Th1 polarizing cytokine, and IL-10, a key cytokine to promote humoral responses, were detected in the supernatant of PBMCs stimulated with dtLLO. These results were reproducible using DCs, confirming the immunostimulatory effect of dtLLO on immune cells from human origin.
Our experiments using a pretreatment of dtLLO with polymyxin B were unable to inhibit cytokine secretion in human cells, confirming that it is dtLLO itself, and not a potential effect mediated by LPS contamination, that is stimulating cytokine production in the assays.
Finally, we decided to explore the mechanism involved in both activation and inflammation induced by dtLLO in human immune cells. A clearer understanding of the immunostimulatory property of dtLLO is a key issue in order to harness the potential of this toxoid for human vaccination. A previous report concerning dtLLO has shown that the toxoid induces up-regulation of co-stimulatory markers and TNF-a mRNA expression in BMDCs from TLR-4 2/2 mice, confirming there is a TLR-4-independent mechanism involved in the proinflammatory activity of dtLLO. Previously, it has been reported that LLO triggers cell signalling in murine J774 cells via spontaneous aggregation of rafts [41] . Lipid rafts aggregation by LLO was independent of its cytolytic activity, but depended upon oligomerization of the monomers. A major observation in that study was that a cholesterol pre-inactivated form of LLO also aggregates lipid rafts independently of pore formation [41] .
Here we studied the role of cholesterol and lipid raft disruption in the activation of human immune cells. Lipid rafts are cholesterol-rich membrane microdomains in the outer leaflet of the plasma membrane. These microdomains regulate membrane key functions in eukaryotic cells, such as signal transduction and vesicular trafficking [42] . Our results demonstrate that plasma membrane cholesterol plays a critical role in the binding and the inflammatory response initiated by dtLLO on human immune cells. Treatment with mbCD clearly inhibited the toxoid binding and also the expression of IL-6 and TNF-a when PBMCs were stimulated by dtLLO. To the best of our knowledge, ours is the first study demonstrating that a mutated and detoxified LLO version retains its proinflammatory activity through a plasma membrane cholesterol-binding mechanism. Our data suggest that cholesterol depletion by mbCD in human immune cells could affect dtLLO binding, and also the integrity of lipid rafts, contributing to the inhibition of the cell signalling induced by dtLLO. Taken together, we have added new data concerning the mechanism by which this LLO mutant could be considered an adjuvant molecule, which is different to the activation of TLRs by natural or synthetics ligands, depot effect or antigen delivery vehicle mechanisms.
Finally, the results observed in fisetin-treated human immune cells confirm that dtLLO induces activation and production of inflammatory mediators using the canonical NF-jB signalling pathway.
In summary, the results shown here confirm that the dtLLO mutant is a safe and effective adjuvant molecule in a mouse model. We also demonstrated that the toxoid exerts its immunostimulatory properties in a cholesterol-dependent mechanism on human immune cells. Taken together, these results supply new evidence concerning dtLLO as a promising adjuvant, not only to enhance the cellular [23] immune response against tumours, as described previously, but also to potentiate the robust humoral responses required for prophylactic antimicrobial vaccines.
